Scholarlink

<p>Oligometastatic non-small cell lung cancer (OM-NSCLC) represents an intermediate disease state between localized and widespread metastatic disease. It is defined by a&#xa0;limited number of metastases and the potential for ablative local therapy. Advances in imaging and molecular diagnostics have enabled improved patient selection for multimodal treatment strategies. Treatment typically combines systemic therapy—including immunotherapy, targeted agents, or chemoimmunotherapy—with local ablative options such as radiotherapy or surgery. Particularly in patients showing stable disease after induction therapy, consolidative local treatment has been shown to improve progression-free (PFS) and potentially overall survival (OS). The choice of optimal local treatment depends on lesion location, patient factors, and interdisciplinary assessment. Favorable prognostic indicators include adenocarcinoma histology, metachronous metastasis, and the absence of nodal disease. For brain metastases, stereotactic radiosurgery (SRS) is a&#xa0;well-tolerated alternative to whole-brain radiotherapy, while surgery remains an option in selected cases with large or symptomatic lesions. All treatment decisions should be guided by a&#xa0;multidisciplinary tumor board. Further prospective studies are needed to define the optimal sequence and value of the individual therapeutic modalities in OM-NSCLC.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Oligometastasiertes Lungenkarzinom

  • 期刊论文

  • 发表日期：

    2025年6月3日

查看全文
  • Rami A. El Shafie,
  • Florian Eichhorn,
  • Hauke Winter,
  • Ursula Nestle,
  • Marcel Kemper,
  • Annalen Bleckmann

摘要

Oligometastatic non-small cell lung cancer (OM-NSCLC) represents an intermediate disease state between localized and widespread metastatic disease. It is defined by a limited number of metastases and the potential for ablative local therapy. Advances in imaging and molecular diagnostics have enabled improved patient selection for multimodal treatment strategies. Treatment typically combines systemic therapy—including immunotherapy, targeted agents, or chemoimmunotherapy—with local ablative options such as radiotherapy or surgery. Particularly in patients showing stable disease after induction therapy, consolidative local treatment has been shown to improve progression-free (PFS) and potentially overall survival (OS). The choice of optimal local treatment depends on lesion location, patient factors, and interdisciplinary assessment. Favorable prognostic indicators include adenocarcinoma histology, metachronous metastasis, and the absence of nodal disease. For brain metastases, stereotactic radiosurgery (SRS) is a well-tolerated alternative to whole-brain radiotherapy, while surgery remains an option in selected cases with large or symptomatic lesions. All treatment decisions should be guided by a multidisciplinary tumor board. Further prospective studies are needed to define the optimal sequence and value of the individual therapeutic modalities in OM-NSCLC.